876310-02-0 Usage
General Description
The chemical "(E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide" is a complex compound with a long and detailed structure. It contains various functional groups including cyano, chloro, ethoxy, and pyridin-2-ylmethoxy. The compound is an amide with a but-2-enamide backbone and a quinolin-6-yl group. It also contains a dimethylamino group and a phenylamino group. With its intricate structure, this compound may have various potential uses in the fields of pharmaceuticals, biochemistry, and materials science, but further research and analysis would be needed to fully understand its properties and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 876310-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,6,3,1 and 0 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 876310-02:
(8*8)+(7*7)+(6*6)+(5*3)+(4*1)+(3*0)+(2*0)+(1*2)=170
170 % 10 = 0
So 876310-02-0 is a valid CAS Registry Number.
876310-02-0Relevant articles and documents
Novel preparation method of epidermal growth factor receptor (EGFR) inhibitor neratinib
-
Paragraph 0030; 0031, (2016/11/21)
The invention relates to a preparation method of an epidermal growth factor receptor (EGFR) inhibitor neratinib. The method is characterized in that 6-[(E)-4-(dimethylamino)-2-butenylamido]-7-ethoxy-4-chloro-3-quinolylmethylnitrile (I) continuously reacts with 2-chloro-3-aminophenol (II) and dichloromethylpyridine hydrochloride (III) to temporarily obtain an intermediate (E)-N-{4-[3-chloro-4-hydroxyanilino]3-cyno-5-ethoxy-6-quinolyl}-4-dimethylamino-2-butenylamide (IV) in order to finally obtain neratinib. The preparation method adopts a continuous reaction process, and dichloromethylpyridine hydrochloride (III) is a catalyst in the first stage of the continuous reaction and is a reaction reagent in the second stage of the continuous reaction, so the method has the advantages of simple and easily available raw materials, high yield, mild reaction conditions, extremely small amount of a generated waste liquid, and high facilitation of industrial production of the above raw medicine.
